Long-Term Clinical Practice Experience with Cinacalcet for Treatment of Hypercalcemic Hyperparathyroidism after Kidney Transplantation

Figure 1

Daily dose of (a) cinacalcet and (b) active vitamin D analogues used during the study. (a) Cinacalcet was initiated in 44 kidney transplant recipients with hypercalcemic hyperparathyroidism and treatment was maintained for a median duration of 6.2 (3.9 to 7.6) years. (b) During the study eight patients received active vitamin D analogues in addition to cinacalcet. The median duration of treatment was 3.3 (2.4 to 4.1) years. Data are presented as medians and interquartile ranges.

(a)

(b)